MedTrace Logo

Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.

NCT05949554 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-03-27

No results posted yet for this study

Summary

Chronic pain symptoms can lead to sleep and mood disorders, restrict domestic and work activities and have a significant impact on quality of life. The prevalence of chronic pain in the general population varies between 10 and 52% depending on the study, 7% of which is neuropathic pain.

Anxiety-depression comorbidities are found in a large number of patients, with harmful consequences on pain since they exacerbate symptoms and their repercussions. Conversely, pain increases psychological distress.

Ketamine has been used in the context of depressive episodes for its rapid action. It is also increasingly used in chronic pain due to its ability to regulate the "wind-up" effect, a phenomenon involved in the central hypersensitization that is inevitably present in neuropathic pain of prolonged duration.

Several studies have found electroencephalographic (EEG) signatures associated with a good antidepressant response to Ketamine. The frequency, absolute and relative power and cordance of the EEG signal in certain frequency ranges (theta, alpha, beta and gamma) could be useful to guide and adapt therapies for depression and pain.

Conditions

  • Neuropathic Pain

Interventions

OTHER

Ketamine infusion

Continuous measurement of burst suppression (BS) (%) and 95% spectral frequency front (SEF95) on frontal EEG Sedline® Masimo Corporation, USA). EEG recording will start 10 minutes before the beginning of infusion until the total amount of 10 milligrams of Ketamine has been infused. The duration varies depending on patient's weight. Each patient will receive a dose of 0,5 mg/kg over a period of time of 2 or 4 hours.

Sponsors & Collaborators

  • INSERM UMR-942, Paris, France

    collaborator OTHER

  • M3DISIM

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Fabrice VALLEE, MD, PhD · Assistance Publique - Hôpitaux de Paris, Lariboisière Hospital, Department of Anesthesiology and Intensive Care

  • Joaquim MATEO, MD · Assistance Publique - Hôpitaux de Paris, Lariboisière Hospital, Department of Anesthesiology and Intensive Care

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-30
Primary Completion
2024-09-30
Completion
2024-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05949554 on ClinicalTrials.gov